Interactive Session:
218. State of the Art: Clinical Management of Hepatitis C
Saturday, October 7, 2017: 10:30 AM-12:00 PM
Room: 06CF

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • compare treatment of HCV infection in adolescents with adults
  • review the principles of treating HCV infection in persons with renal insufficiency
  • recognize causes of liver disease after SVR

Target Audience: Academicians, Clinicians, Fellows, HIV clinicians, Infectious diseases pediatricians, Infectious diseases physicians, Pharmacists

Tracks: Trainee, Pediatric ID, HIV-STD-TB, Adult ID


Moderators:  Susanna Naggie, MD, MHS, Duke Clinical Research Institute and David Thomas, MD, MPH, FIDSA, Johns Hopkins University School of Medicine

Interactive Panelists:  Ravi Jhaveri, MD, FIDSA, FPIDS, University of North Carolina , David L. Wyles, MD, Denver Health Medical Center and Kenneth Sherman, MD, University Cincinnati College of Medicine

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-311-L01-P

Disclosures:

S. Naggie, Abbvie: Grant Investigator , Research support
BMS: Grant Investigator , Research support
Gilead Sciences: Consultant and Grant Investigator , a grant partially supports my salary and Research grant
IAS-USA: Speaker's Bureau , generates revenue for Duke
Janssen Pharmaceutical: Grant Investigator , Research support
Mentor Meetings: Speaker's Bureau , generates revenue for Duke
Merck: Grant Investigator , Research support
Platform Q Health Inc.: Speaker's Bureau , generates revenue for Duke
Practice Point Communications: Speaker's Bureau , generates revenue for Duke
Clinical Care Options: Speaker's Bureau , generates revenue for Duke
Vindico: Speaker's Bureau , generates revenue for Duke
Tacere: Grant Investigator , Research support

D. Thomas, UpToDate: Editor , Salary
Oxford University Press: Editor , Salary
Merck: Scientific Advisor , Consulting fee

R. Jhaveri, Gilead: Investigator , Research support
Abbvie: Investigator , Research support
Merck: Grant Investigator , Research grant

D. L. Wyles, AbbVie: Consultant , Research Contractor and Scientific Advisor , Consulting fee and Research support
Gilead: Consultant , Grant Investigator and Research Contractor , Consulting fee , Research grant and Research support
Merck: Consultant and Research Contractor , Consulting fee and Research support

K. Sherman, AbbVie: Investigator , Research grant
BMS: Grant Investigator , Grant recipient
Gilead: Investigator and Scientific Advisor , Consulting fee and Research grant
Merck: Grant Investigator , Investigator and Scientific Advisor , Consulting fee and Research grant
MedImmune: Grant Investigator and Scientific Advisor , Consulting fee and Research grant
Intercept: Investigator , Research grant
Watermark: Scientific Advisor , Consulting fee
MedPace: Scientific Advisor , Consulting fee

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.